NEW YORK, Sept. 30 - Venture capitalists turned their backs on privately held genomics companies during the third quarter as private-equity markets sought solace among drug discoverers and developers, according to an industry report.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.